Virchow Biotech
Biosimilar developer, India. 2 development products across 2 molecules: pegfilgrastim, rituximab.
First approval in the Atlas: Dec 2021, Virchow Biotech (INN only), pegfilgrastim (CDSCO)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved2
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Pegfilgrastim | Virchow Biotech pegfilgrastim | · | · | · | · | Dec 2021 | · |
| Rituximab | Virchow Biotech rituximab | · | · | · | · | Aug 2025 | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- CDSCODec 2021Virchow Biotech (INN only), pegfilgrastim
- CDSCOAug 2025Virchow Biotech Private (INN only), rituximab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.